Sartorius Stedim Biotech Stock Today
| SDMHF Stock | USD 223.90 7.90 3.66% |
PerformanceMild
| Odds Of DistressLow
|
Sartorius Stedim is trading at 223.90 as of the 24th of November 2025. This is a 3.66% up since the beginning of the trading day. The stock's lowest day price was 223.9. Sartorius Stedim has less than a 9 % chance of experiencing financial distress in the next few years but had a somewhat mild performance during the last 90 days. The performance scores are derived for the period starting the 26th of August 2025 and ending today, the 24th of November 2025. Click here to learn more.
Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG. Sartorius Stedim operates under Medical Instruments Supplies classification in the United States and is traded on OTC Exchange. The company has 92.17 M outstanding shares. More on Sartorius Stedim Biotech
Moving together with Sartorius Pink Sheet
Moving against Sartorius Pink Sheet
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Sartorius Pink Sheet Highlights
| Chairman of The Board and CEO | Joachim Kreuzburg |
| Business Concentration | Medical Instruments & Supplies, Healthcare (View all Sectors) |
Sartorius Stedim Biotech [SDMHF] is a Pink Sheet which is traded between brokers as part of OTC trading. The company currently falls under 'Large-Cap' category with a current market capitalization of 34.9 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Sartorius Stedim's market, we take the total number of its shares issued and multiply it by Sartorius Stedim's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Sartorius Stedim Biotech classifies itself under Healthcare sector and is part of Medical Instruments & Supplies industry. The entity has 92.17 M outstanding shares.
Sartorius Stedim Biotech has accumulated about 161.7 M in cash with 695.97 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.75.
Check Sartorius Stedim Probability Of Bankruptcy
Ownership AllocationSartorius Stedim Biotech shows a total of 92.17 Million outstanding shares. Sartorius Stedim Biotech has majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 73.81 % of Sartorius Stedim outstanding shares that are owned by insiders indicates they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Sartorius Ownership Details
Sartorius Stedim Biotech Risk Profiles
| Mean Deviation | 1.66 | |||
| Semi Deviation | 2.0 | |||
| Standard Deviation | 2.83 | |||
| Variance | 8.0 |
Sartorius Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Sartorius Stedim without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Economic Indicators Now
Economic IndicatorsTop statistical indicators that provide insights into how an economy is performing |
| All Next | Launch Module |
Sartorius Stedim Corporate Management
| Heiko Imhl | VP Relations | Profile | |
| Olivier Guitard | Head BPS | Profile | |
| Benedikt Orzelek | Investor Relations Contact | Profile | |
| John Mackay | Sales Marketing | Profile |
Other Information on Investing in Sartorius Pink Sheet
Sartorius Stedim financial ratios help investors to determine whether Sartorius Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sartorius with respect to the benefits of owning Sartorius Stedim security.